Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis.

Denna dubbelblinda fas IIa-studie omfattade personer i Puerto Rico och Honduras med Helicobacter pylori-negativa premaligna tillstånd i magsäcken: multifokal atrofisk gastrit eller intestinal metaplasi i magsäcken. Femtio av 110 screenade deltagare randomiserades 1:1 till 1 000 mg/dag av kurkuminformuleringen Meriva eller placebo i 6 månader; 48 fullföljde studien. Endoscopy was performed at baseline and 6 months. The primär endpoint, gastric-body mucosal IL1β, fell significantly from baseline in the Meriva group (p=0.032). That is an inflammatory biomarker rather than cancer incidence. The two groups showed similar changes in IL8, TNFα, inducible protein 10, gastric histology, and DNA damage measured by γ-H2AX phosphorylation. Meriva was reported as safe and well tolerated. The study therefore found a signal in one cytokine but did not show improved tissue pathology or DNA-damage measures over 6 months. It does not establish that curcumin prevents gastric cancer, and it does not address healthy adults. The authors call for further studies, including in H. pylori-positive people.

Meriva was safe and well tolerated and was associated with a potential reduction in gastric inflammation measured by mucosal IL1β.